[go: up one dir, main page]

CO2018001264A2 - Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos - Google Patents

Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos

Info

Publication number
CO2018001264A2
CO2018001264A2 CONC2018/0001264A CO2018001264A CO2018001264A2 CO 2018001264 A2 CO2018001264 A2 CO 2018001264A2 CO 2018001264 A CO2018001264 A CO 2018001264A CO 2018001264 A2 CO2018001264 A2 CO 2018001264A2
Authority
CO
Colombia
Prior art keywords
baff
activating factor
compound targeting
lymphocyte activating
compounds
Prior art date
Application number
CONC2018/0001264A
Other languages
English (en)
Inventor
S Leslie Johnson
Sanjaya Singh
Qi Pan
Rachel Rebecca Barrett
Pankaj Gupta
Sarah Low
Haixia Wu
Original Assignee
Boehringer Ingelheim Int
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Macrogenics Inc filed Critical Boehringer Ingelheim Int
Publication of CO2018001264A2 publication Critical patent/CO2018001264A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

La descripción se refiere a compuestos específicos para IL23A y BAFF, composiciones que comprenden los compuestos y métodos de uso de estos. También se describen ácidos nucleicos, células y métodos de producción relacionados con los compuestos y las composiciones.
CONC2018/0001264A 2015-07-23 2018-02-07 Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos CO2018001264A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US201662355302P 2016-06-27 2016-06-27
PCT/US2016/043267 WO2017015433A2 (en) 2015-07-23 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Publications (1)

Publication Number Publication Date
CO2018001264A2 true CO2018001264A2 (es) 2018-05-10

Family

ID=57835236

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0001264A CO2018001264A2 (es) 2015-07-23 2018-02-07 Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos

Country Status (21)

Country Link
US (3) US10280231B2 (es)
EP (1) EP3322436A4 (es)
JP (1) JP6866345B2 (es)
KR (1) KR102644875B1 (es)
CN (1) CN108135976B (es)
AU (1) AU2016297575B2 (es)
BR (1) BR112018001255A2 (es)
CA (1) CA2993329A1 (es)
CL (1) CL2018000182A1 (es)
CO (1) CO2018001264A2 (es)
EA (1) EA201890360A1 (es)
IL (1) IL256665B2 (es)
MX (1) MX2018000959A (es)
MY (1) MY191081A (es)
PE (1) PE20180774A1 (es)
PH (2) PH12021552628A1 (es)
SA (1) SA518390788B1 (es)
SG (1) SG10201912593VA (es)
TW (2) TWI861413B (es)
UA (1) UA125433C2 (es)
WO (1) WO2017015433A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
JP6758304B2 (ja) 2015-02-04 2020-09-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
EA201890360A1 (ru) * 2015-07-23 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN117916273A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 抗il23抗体融合蛋白及用途
EP4642812A1 (en) * 2022-12-28 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof
TW202525323A (zh) * 2023-07-06 2025-07-01 大陸商榮昌生物製藥（煙臺）股份有限公司 用ＴＡＣＩ－Ｆｃ融合蛋白治療ＡＮＣＡ相關性血管炎的方法
TW202540171A (zh) 2024-02-06 2025-10-16 美商派拉岡醫療公司 Ｉｌ－２３抗體組合物及使用方法
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7138501B2 (en) * 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
KR101599735B1 (ko) 2007-06-21 2016-03-07 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
KR101620539B1 (ko) 2007-12-21 2016-05-13 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
SG188142A1 (en) 2008-05-09 2013-03-28 Abbott Gmbh & Co Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
RU2593720C2 (ru) * 2008-12-19 2016-08-10 Макродженикс, Инк. Ковалентные диантитела и их применение
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
SI3053932T1 (sl) * 2010-02-19 2021-01-29 Xencor, Inc. Novi CTLA4-IG imunoadhezini
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
JP5964300B2 (ja) * 2010-08-02 2016-08-03 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
JP5972915B2 (ja) * 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
TR201808458T4 (tr) 2012-02-15 2018-07-23 Hoffmann La Roche FC-reseptör bazlı afinite kromatografisi.
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
ES2711554T3 (es) * 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
EP2934577A1 (en) 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
US10435474B2 (en) * 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) * 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
EA201890360A1 (ru) * 2015-07-23 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение

Also Published As

Publication number Publication date
US11884744B2 (en) 2024-01-30
JP6866345B2 (ja) 2021-04-28
SA518390788B1 (ar) 2021-12-26
TWI861413B (zh) 2024-11-11
MY191081A (en) 2022-05-30
US20190241678A1 (en) 2019-08-08
US10844138B2 (en) 2020-11-24
WO2017015433A3 (en) 2017-03-09
NZ778160A (en) 2025-05-02
EP3322436A2 (en) 2018-05-23
CL2018000182A1 (es) 2018-08-31
BR112018001255A2 (pt) 2018-09-11
UA125433C2 (uk) 2022-03-09
EA201890360A1 (ru) 2018-06-29
PE20180774A1 (es) 2018-05-07
NZ738942A (en) 2025-05-02
MX2018000959A (es) 2018-06-06
TW202144411A (zh) 2021-12-01
AU2016297575A1 (en) 2018-02-15
IL256665B1 (en) 2023-06-01
US10280231B2 (en) 2019-05-07
IL256665A (en) 2018-02-28
IL256665B2 (en) 2023-10-01
CN108135976A (zh) 2018-06-08
JP2018527323A (ja) 2018-09-20
CA2993329A1 (en) 2017-01-26
AU2016297575B2 (en) 2021-05-27
KR102644875B1 (ko) 2024-03-06
PH12021552628A1 (en) 2022-06-27
KR20180028522A (ko) 2018-03-16
US20170022294A1 (en) 2017-01-26
US20210107998A1 (en) 2021-04-15
PH12018500151A1 (en) 2018-07-30
TWI733685B (zh) 2021-07-21
TW201712030A (zh) 2017-04-01
EP3322436A4 (en) 2019-03-27
WO2017015433A2 (en) 2017-01-26
CN108135976B (zh) 2022-10-18
SG10201912593VA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CO2018001264A2 (es) Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
CL2025001440A1 (es) Medios y método para preparar vectores virales y usos de los mismos
CL2017002155A1 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018000194A1 (es) Compuestos de piridina
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
UY35467A (es) Compuestos orgánicos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
UY35796A (es) ?derivados de dihidrohidantoína sustituidos, procesos para prepararlos, composiciones herbicidas y su uso en plantas?.
CO2019006687A2 (es) Polimorfos
MX2016004565A (es) Preparacion de derivados de hidroxi - bencilbenceno.
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CL2019001804A1 (es) Activador de nrf2.